Cikkek nyilvánosan hozzáférhető megbízással - Brian DoughertyTovábbi információ
Valahol hozzáférhető: 15
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
KS Thress, CP Paweletz, E Felip, BC Cho, D Stetson, B Dougherty, Z Lai, ...
Nature medicine 21 (6), 560-562, 2015
Megbízások: US National Institutes of Health
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, ...
Annals of Oncology 29 (5), 1203-1210, 2018
Megbízások: US National Institutes of Health, Cancer Research UK, European Commission …
Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial
P Schmid, J Abraham, S Chan, D Wheatley, AM Brunt, G Nemsadze, ...
Journal of Clinical Oncology 38 (5), 423-433, 2020
Megbízások: Cancer Research UK, National Institute for Health Research, UK
Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models
CA Eberlein, D Stetson, AA Markovets, KJ Al-Kadhimi, Z Lai, PR Fisher, ...
Cancer research 75 (12), 2489-2500, 2015
Megbízások: US National Institutes of Health, V Foundation, USA
AKT Inhibition in Solid Tumors With AKT1 Mutations
DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ...
Journal of Clinical Oncology 35 (20), 2251-2259, 2017
Megbízások: US National Institutes of Health, Cancer Research UK
Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer
EN Tcyganov, S Hanabuchi, A Hashimoto, D Campbell, G Kar, TWF Slidel, ...
The Journal of clinical investigation 131 (16), 2021
Megbízások: US National Institutes of Health
Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients
J Guinney, C Ferté, J Dry, R McEwen, G Manceau, KJ Kao, KM Chang, ...
Clinical Cancer Research 20 (1), 265-272, 2014
Megbízások: US National Institutes of Health
Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
A Ewing, A Meynert, M Churchman, GR Grimes, RL Hollis, CS Herrington, ...
Clinical Cancer Research 27 (11), 3201-3214, 2021
Megbízások: Cancer Research UK, Chief Scientist Office, Scottish Executive, UK …
Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance
V Serra, AT Wang, M Castroviejo-Bermejo, UM Polanska, M Palafox, ...
Clinical Cancer Research 28 (20), 4536-4550, 2022
Megbízások: US National Institutes of Health, Cancer Research UK, European Commission …
Multiomic characterization of high-grade serous ovarian carcinoma enables high-resolution patient stratification
RL Hollis, AM Meynert, CO Michie, T Rye, M Churchman, A Hallas-Potts, ...
Clinical Cancer Research 28 (16), 3546-3556, 2022
Megbízások: Cancer Research UK, UK Medical Research Council, Target Ovarian Cancer, UK
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
GP Collins, TN Clevenger, KA Burke, B Yang, A MacDonald, ...
Leukemia & Lymphoma 62 (11), 2625-2636, 2021
Megbízások: Cancer Research UK, National Institute for Health Research, UK
Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases
J Mitchell, N Camacho, P Shea, KH Stopsack, V Joseph, O Burren, ...
medRxiv, 2024
Megbízások: British Heart Foundation, Cancer Research UK, UK Medical Research Council …
Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer
A Ewing, A Meynert, R Silk, S Aitken, DP Bendixsen, M Churchman, ...
bioRxiv, 2024.01. 12.575376, 2024
Megbízások: Cancer Research UK, Chief Scientist Office, Scottish Executive, UK Medical …
Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases
J Mitchell, N Camacho, P Shea, KH Stopsack, V Joseph, OS Burren, ...
Nature Communications 16 (1), 1779, 2025
Megbízások: Cancer Research UK, UK Medical Research Council, National Institute for …
Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma
RL Hollis, M Churchman, GR Grimes, AM Meynert, P Gautier, L McMahon, ...
European Journal of Cancer, 115299, 2025
Megbízások: Cancer Research UK, UK Medical Research Council
A publikációs és a finanszírozási adatokat számítógépes program határozza meg, automatikusan.